Pharmaceutical manufacturers of Doxycycline

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad, deep-scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred Contract Development and Manufacturing Organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 80 billion doses of nearly 8,000 products annually. Its rapidly growing expert workforce exceeds 18,000, including more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, Catalent, Inc. (NYSE:CTLT), is in S&P 500® company, and generated nearly $5 billion in revenue in its 2022 fiscal year.

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

Established in 1978 as a specialized facility for Small Volume Parenterals (SVPs), Gland Pharma has evolved into a forward-thinking and quality-focused organization catering to the pharmaceutical requirements of diverse global markets. The company possesses state-of-the-art facilities for injectables established in partnership with Vetter Group, Germany, providing Gland Pharma a technological advantage in injectables, particularly in Pre Filled Syringes.

We at Raks are dedicated to develop and manufacture active pharmaceutical ingredients and intermediates. We are committed to create value through intellectual property, quality systems and customer relation across the globe. We are research driven company providing cost effective and environmental friendly technologies with safety and quality as primary focus.

Hovione brings over six decades of experience as a CDMO and serves as a specialized integrated provider delivering solutions for drug substance, drug product intermediate, and drug product. With four FDA examined facilities in the United States, China, Ireland, and Portugal, as well as research laboratories in Portugal and the United States, the company supplies pharmaceutical customers with services for the development and compliant production of innovative drugs, including highly potent compounds. Hovione delivers a comprehensive range of development services and manufacturing capabilities in particle engineering such as Spray Drying.

Maithri Drugs stands as one of the rapidly emerging pharmaceutical firms in India. Maithri's primary emphasis is on active pharmaceutical ingredients (APIs). The corporation is widely acknowledged for its exceptional research & development and ambitious expansion approaches. Our 125+Global DMFs, including 50 in the United States and 22 in the EU within a brief duration, bear witness to our R&D superiority. Maithri's production site is situated in Hyderabad. This site is scrutinized and endorsed by the US FDA. Furthermore, our facility is accredited in accordance with the criteria of DCGI, WHO GMP, and ISO 9001.

Established in 1993, SUANFARMA is a business-to-business partner in the field of life sciences specializing in the formulation, manufacture, and marketing of components for the pharmaceutical, veterinary, and nutraceutical sectors. In SUANFARMA, we provide our CDMO capabilities for fermentation and chemical synthesis projects, delivering a comprehensive service with a proven track record, facilitating success in the formulation, expansion, production, and marketing of an API, whether it is innovative or generic

Zim offers innovative solutions for administering medications, focusing on enhancing patient convenience and compliance. The company utilizes its own advanced technologies, such as modified release and taste masking, to create and produce distinct pharmaceutical products. Their range includes oral solid dosage formulations and pre-formulations (PFI), encompassing tablets, capsules, dry syrups, pellets, granules, and orally disintegrating strips (ODS). Additionally, they provide services for site transfer/variation for sustained release tablets, oral disintegrating tablets, fast disintegrating capsules, and more.

Changzhou Pharmaceutical Factory (CPF) is a subsidiary company of Shanghai Pharma Holdings Co., Ltd., It is headquartered in Changzhou, Jiangsu province, China, Changzhou pharmaceutical Factory has a rich history & Lineage in the pharmaceutical sector. The company was founded in 1949 by (Tan Ruiting) with a registered capital 108 million yuan and the company was restructured as a Changzhou pharmaceutical Factory under the aegis of Shanghai Pharma Group. The Chinese business of Changzhou pharmaceutical factory was full fledged sales & marketing organization,Changzhou Pharma is a one of the prominent players in the Chinese pharmaceutical formulations market with a strong foothold across multiple therapies. The company have more than 1500 employees across the country and has earned a reputation amongest the Chinese pharmaceutical companies for providing innovative, comprehensive and complete healthcare solutions. At Changzhou pharmaceutical Factory, we have one of the strongest global commercial infrastructures in the industry, with a balanced reach across US, Europe, the Asia Pacific region and emerging markets. Our high quality manufacturing dedicated facilities for Oncology, Non Oncology, Complex Generics, OTC-Products and sterile injectables, scientific excellence and vast supply chain network to improve access to medicine for patients worldwide. The company mainly involves leading pharmaceutical manufacturer a wide range of key Intermediates, Active pharmaceutical ingredients, Finished Formulations meet with global standards, Changzhou Pharmaceutical Factory it covers an area of 300,000㎡ including R&D, dedicated manufacturing, international marketing office. And we maintain an industry -leading pipeline, composed of numerous complex generics and state owned brands. The company annually brings 800 tons of API's and 3000 millions of Finished dosage forms across the Globe.

Kukjeon Pharmaceutical has been actively contributing to the advancement of South Korea's pharmaceutical industry by supplying active pharmaceutical ingredients (API) developed through 50 years of professional capacity building. Currently, we provide API to more than 200 pharmaceutical and electronics companies domestically and internationally. We are a comprehensive chemical solution provider offering a wide range of chemical-based products and services, supported by an organizational system and the capability to engage in research and development as well as foundational businesses.

Yangzhou Liberty Pharmaceutical Co Ltd operates as an API manufacturer and a collaborative enterprise rooted in Yangzhou Pharmaceutical Co Ltd. In 2013, our firm took over Datong Tongxing Antibiotic Co Ltd in Shanxi Province, solidifying our position as the holding company. In addition to our current operations, we are dedicated to the development and manufacture of alternative fermentation raw materials. Leveraging an advanced quality control system, several of our products have successfully navigated rigorous assessments, including inspection by the US FDA, as well as securing COS, EU-GMP, and GMP certifications. Anhui Liberty Pharmaceutical Co Ltd and Datong Tongxing Antibiotic Co Ltd are also integral parts of our enterprise.

CTTQ is a multinational pharmaceutical company with integrated R&D, manufacturing, marketing, sales and distribution capabilities. It is the core enterprise of Sino Biopharmaceutical (01177.HK). With more than 14000 employees, CTTQ is well-known in the field of anti-tumor and liver disease in China. It is ranked 15th on the list of the “Top 100 Pharmaceutical Enterprises in China” in 2020, and among the top 5 most innovative Pharmaceutical Enterprises, and top 10 fastest-growing Pharmaceutical Manufacturers in China.